KR20220080102A - B형 간염에 대한 인간 중화 항체와 관련된 조성물 및 방법 - Google Patents

B형 간염에 대한 인간 중화 항체와 관련된 조성물 및 방법 Download PDF

Info

Publication number
KR20220080102A
KR20220080102A KR1020227011839A KR20227011839A KR20220080102A KR 20220080102 A KR20220080102 A KR 20220080102A KR 1020227011839 A KR1020227011839 A KR 1020227011839A KR 20227011839 A KR20227011839 A KR 20227011839A KR 20220080102 A KR20220080102 A KR 20220080102A
Authority
KR
South Korea
Prior art keywords
ser
gly
prt
homo sapiens
tyr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227011839A
Other languages
English (en)
Korean (ko)
Inventor
차오 왕
미첼 누센즈웨이그
Original Assignee
더 락커펠러 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 락커펠러 유니버시티 filed Critical 더 락커펠러 유니버시티
Publication of KR20220080102A publication Critical patent/KR20220080102A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/082—Hepadnaviridae (F), e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020227011839A 2019-09-11 2020-09-11 B형 간염에 대한 인간 중화 항체와 관련된 조성물 및 방법 Pending KR20220080102A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962898735P 2019-09-11 2019-09-11
US62/898,735 2019-09-11
US202062982276P 2020-02-27 2020-02-27
US62/982,276 2020-02-27
PCT/US2020/050509 WO2021050954A1 (en) 2019-09-11 2020-09-11 Compositions and methods related to human neutralizing antibodies to hepatitis b

Publications (1)

Publication Number Publication Date
KR20220080102A true KR20220080102A (ko) 2022-06-14

Family

ID=74866658

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227011839A Pending KR20220080102A (ko) 2019-09-11 2020-09-11 B형 간염에 대한 인간 중화 항체와 관련된 조성물 및 방법

Country Status (7)

Country Link
US (1) US20220315645A1 (https=)
EP (1) EP4021503A4 (https=)
JP (1) JP7629649B2 (https=)
KR (1) KR20220080102A (https=)
CN (1) CN114728066A (https=)
CA (1) CA3154556A1 (https=)
WO (1) WO2021050954A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023287352A2 (en) * 2021-07-15 2023-01-19 National University Of Singapore Anti-hbv antibodies and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01500515A (ja) * 1986-06-20 1989-02-23 スクリップス　クリニック　アンド　リサーチ　ファウンデーション Ｂ型肝炎ウィルス表面抗原のプレｓ領域のｔ及びｂ細胞エピトープ
US7390619B1 (en) * 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
CA2594922A1 (en) * 2005-01-14 2006-07-20 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Monoclonal antibodies that bind or neutralize hepatitis b virus
CA2799746C (en) * 2010-05-17 2020-11-24 Sai Reddy Rapid isolation of monoclonal antibodies from animals
AU2013287516B2 (en) * 2012-07-10 2016-07-07 Green Cross Corporation An antibody composition for prevention or treatment of mutant hepatitis B virus infection
KR20150070181A (ko) * 2012-09-27 2015-06-24 크루셀 홀란드 비.브이. B형 간염 바이러스에 결합하고 이를 중화시킬 수 있는 인간 결합 분자 및 그의 용도
SG10201804975PA (en) * 2013-12-12 2018-07-30 Broad Inst Inc Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for HBV and Viral Diseases and Disorders
US10167333B2 (en) * 2014-01-16 2019-01-01 Mario Umberto Francesco Mondelli Neutralizing human monoclonal antibodies against hepatitis B virus surface antigen
WO2018064611A1 (en) * 2016-09-30 2018-04-05 Baylor College Of Medicine Antibody based gene therapy with tissue-directed expression

Also Published As

Publication number Publication date
EP4021503A4 (en) 2024-02-14
CA3154556A1 (en) 2021-03-18
JP2022547551A (ja) 2022-11-14
WO2021050954A1 (en) 2021-03-18
EP4021503A1 (en) 2022-07-06
CN114728066A (zh) 2022-07-08
JP7629649B2 (ja) 2025-02-14
US20220315645A1 (en) 2022-10-06

Similar Documents

Publication Publication Date Title
Wang et al. A combination of human broadly neutralizing antibodies against hepatitis B virus HBsAg with distinct epitopes suppresses escape mutations
JP7171809B2 (ja) Ｂ型肝炎ウイルスを強力に中和する抗体及びその使用
Hehle et al. Potent human broadly neutralizing antibodies to hepatitis B virus from natural controllers
AU2015206002B2 (en) Neutralizing human monoclonal antibodies against Hepatitis B Virus surface antigen
WO2013185558A1 (zh) 用于治疗hbv感染及相关疾病的多肽及抗体
CN114630680B (zh) 用于治疗乙型肝炎病毒感染的抗体组合物和方法
TWI904172B (zh) 抗hbv抗體及使用方法
KR20220080102A (ko) B형 간염에 대한 인간 중화 항체와 관련된 조성물 및 방법
Kim et al. Construction of a humanized antibody to hepatitis B surface antigen by specificity-determining residues (SDR)-grafting and de-immunization
US20240327500A1 (en) Anti-hbv antibodies and uses thereof
RU2803082C2 (ru) Антитела против вируса гепатита в и их применение
HK40074417A (en) Antibodies that neutralize hepatitis b virus and uses thereof
HK40074418A (en) Antibodies that neutralize hepatitis b virus and uses thereof
CN117042797A (zh) 用于治疗乙型肝炎病毒感染的组合物和方法
HK40073510B (zh) 用於治疗乙型肝炎病毒感染的抗体组合物和方法
HK40073510A (en) Antibody compositions and methods for treating hepatitis b virus infection
Shamseldin Development of Research Tools for Studying Hepatitis B Virus

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000